Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Zika virus kills brain cancer cells - study
The Zika virus, which is spread my mosquitoes, causes serious birth defects.
Findings may be used to treat fatal disease 

A study by US researchers has revealed that Zika virus can kill brain cancer stem cells - the type of cells that are most resistant to standard treatment.

Their findings, published in the Journal of Experimental Medicine, suggest that Zika virus - which causes serious birth defects in humans - could be directed at malignant cells in the brain.

Researchers say their findings have the potential to improve people’s chances against glioblastoma - the most common form of primary brain tumour in adults.

“We showed that Zika virus can kill the kind of glioblastoma cells that tend to be resistant to current treatments and lead to death,” explained co-author Michael Diamond, a professor of Medicine at Washington University School of Medicine.

In the study, researchers from Washington University School of Medicine and the University of California San Diego School of Medicine assessed if the virus could kill stem cells in glioblastomas removed from patients at diagnosis.

Their findings suggest that Zika infection and chemotherapy/radiotherapy compliment each other. While the standard treatment kills the majority of the tumour cells but often leads the stem cells intact, Zika virus attacks the stem cells but bypasses the greater part of the tumour.

“We see Zika one day being used in combination with current therapies to eradicate the whole tumour,” said Chheda, an assistant professor of medicine and neurology.

To see if Zika could be used to treat cancer in a living animal, the researchers injected either Zika virus or salt water (a placebo) into the brain tumours of mice. They found that tumours were markedly smaller in the Zika treated mice two weeks after injection, and those mice survived much longer than the ones injected with salt water.

Researchers say that if Zika virus was to be used in humans, it would have to be injected straight into the brain. If injected anywhere else in the body, the immune system would destroy it before it reaches the brain.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.